IL-25 and Type 2 Innate Lymphoid Cells Induce Pulmonary Fibrosis
IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis Emily Hamsa,b, Michelle E. Armstronga,b, Jillian L. Barlowc, Sean P. Saundersa,b, Christian Schwartzd, Gordon Cookee, Ruairi J. Fahyf, Thomas B. Crottyg, Nikhil Hiranih, Robin J. Flynnc, David Voehringerd, Andrew N. J. McKenziec, Seamas C. Donnellye,i, and Padraic G. Fallona,b,j,1 aTrinity Biomedical Sciences Institute, School of Medicine, Trinity College Dublin, Dublin 2, Ireland; bNational Children’s Research Centre, Our Lady’s Children’s Hospital, Dublin 8, Ireland; cMedical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom; dDepartment of Infection Biology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany; eSchool of Medicine and Medical Science, University College Dublin, Dublin 4, Ireland; fSt. James’s Hospital, Dublin 8, Ireland; gDepartment of Pathology, St. Vincent’s University Hospital, Dublin 4, Ireland; hMedical Research Council Centre for Inflammation Research, University of Edinburgh, Edinburgh EH16 4SB, United Kingdom; iNational Pulmonary Fibrosis Referral Centre, St. Vincent’s University Hospital, Dublin 4, Ireland; and jInstitute of Molecular Medicine, School of Medicine, Trinity College Dublin, St. James’s Hospital, Dublin 8, Ireland Edited by Shigeo Koyasu, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, and accepted by the Editorial Board November 15, 2013 (received for review August 26, 2013) Disease conditions associated with pulmonary fibrosis are pro- fibrosis in experimental mouse models, via the activation of IL-13– gressive and have a poor long-term prognosis with irreversible producing ILC2. We also observe increases in both IL-25 and ILC2 changes in airway architecture leading to marked morbidity and in the lung of patients with idiopathic pulmonary fibrosis (IPF).
[Show full text]